These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 6624210)

  • 1. [Elantan in coronary heart disease. Report of experiences].
    Jahed M
    ZFA (Stuttgart); 1983 Aug; 59(22):1234-5. PubMed ID: 6624210
    [No Abstract]   [Full Text] [Related]  

  • 2. [Hemodynamic effects of isosorbide-5-mononitrate in ischemic cardiopathy].
    Russo G; Tolaro S; Monaco O; Greco G; Grassi R; Monaco A; Calvi V; Felis S; Tamburino C; Giuffrida G
    Cardiologia; 1988 Mar; 33(3):291-5. PubMed ID: 3401892
    [No Abstract]   [Full Text] [Related]  

  • 3. [Treatment of coronary disease with elantan. Results of a multicenter study].
    van Hasselt P; Weiss M; Haase W
    Fortschr Med; 1984 Jan; 102(1-2):55-60. PubMed ID: 6365709
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of nitroglycerin and isosorbiddinitrate on myocardial perfusion and hemodynamics in patients with and without coronary disease.
    Simon R; Amende I; Engel HJ; Lichtlen PR
    Scand J Clin Lab Invest Suppl; 1984; 173():47-58. PubMed ID: 6442002
    [No Abstract]   [Full Text] [Related]  

  • 5. [Changes of the systolic variations of the left ventricle induced by isosorbitol dinitrate in patients with chronic coronary insufficiency].
    Savioli RM; Del Nero E; Ortiz J; Rangel FA; Barretto AC; Papaléo Netto M; Diament J; Tranchesi J
    Arq Bras Cardiol; 1977 Dec; 30(6):441-4. PubMed ID: 614003
    [No Abstract]   [Full Text] [Related]  

  • 6. Isosorbide dinitrate-induced improvement in left ventricular ejection fraction during exercise in coronary arterial disease.
    Steele PP; Rainwater J; Jensen D; Vogel RA; Battock D
    Chest; 1978 Nov; 74(5):526-30. PubMed ID: 738090
    [No Abstract]   [Full Text] [Related]  

  • 7. [Ergometric study of the association of a beta-blocker and a nitrate derivative].
    Jullien G
    Nouv Presse Med; 1978 Sep; 7(31):2727-31. PubMed ID: 30951
    [No Abstract]   [Full Text] [Related]  

  • 8. [Isosorbide dinitrate and bupranolol in the therapy of coronary heart disease (author's transl)].
    Pascal N; Eggert R
    Arzneimittelforschung; 1978; 28(5):847-50. PubMed ID: 373775
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [5-isosorbide mononitrate at rest and on exercise in coronary heart disease: acute and long-term effect].
    Jansen W; Osterspey A; Tauchert M; Schmid G; Schell U; Fuchs M; Hombach V; Hilger HH
    Dtsch Med Wochenschr; 1982 Oct; 107(40):1499-506. PubMed ID: 7117166
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Combined treatment of coronary heart disease with diltiazem and isosorbide dinitrate].
    Beythien RD
    Dtsch Med Wochenschr; 1983 Feb; 108(5):176-80. PubMed ID: 6402353
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic effectiveness of isosorbide-5-mono nitrate in the treatment of exertion myocardial ischemia].
    Cassottana P; Torre F; Bafico GL; Oddone D; Vinci P; Gatto R; Borgo E
    Minerva Cardioangiol; 1987; 35(1-2):79-82. PubMed ID: 3561813
    [No Abstract]   [Full Text] [Related]  

  • 12. [Hemodynamic changes at rest and during stress following isosorbide-5-mononitrate therapy in patients with coronary disease].
    Isbary J; Doering W; Wauer B; Greding H; König E
    Med Welt; 1981 Apr; 32(14A):530-4. PubMed ID: 7242315
    [No Abstract]   [Full Text] [Related]  

  • 13. Hemodynamic effects of isosorbide-5-mononitrate in acute and chronic treatment of coronary heart disease.
    Schuster P; Trieb G; Wiechmann HW
    Z Kardiol; 1983; 72 Suppl 3():251-4. PubMed ID: 6666229
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of pharmacokinetics and pharmacodynamics of one-week monotherapy with IS-5-N s.r. 50 or 100 mg, ISDN s.r. 120 mg or IS-5-N 2 x 20 mg in coronary heart disease patients.
    Jansen W; Prenzel R; Düring C; Rappert B; Geppert R
    Int J Clin Pharmacol Ther Toxicol; 1992 Nov; 30(11):504-5. PubMed ID: 1490808
    [No Abstract]   [Full Text] [Related]  

  • 15. [Long-term haemodynamic effect of high doses of isosorbid dinitrate (80 mg) in slow-release form in coronary heart disease (author's transl)].
    Wolf R; Sinn R; Guillen R; Koeffler H
    Dtsch Med Wochenschr; 1981 Sep; 106(36):1130-4. PubMed ID: 7261938
    [No Abstract]   [Full Text] [Related]  

  • 16. [Left ventricular function parameters following administration of isosorbide-5-mononitrate].
    Bergbauer M
    Med Welt; 1983 Jun; 34(22):642-4. PubMed ID: 6877071
    [No Abstract]   [Full Text] [Related]  

  • 17. [Study of the efficacy of a beta-blocker, a nitrate derivative of their combination in 20 patients undergoing an exercise test].
    Jullien G; Balansard P; Luccioni R; Gérard R
    Coeur Med Interne; 1977; 16(1):111-23. PubMed ID: 852245
    [No Abstract]   [Full Text] [Related]  

  • 18. [Long-term tolerance and effect of isosorbide-5-mononitrate in comparison to isosorbide dinitrate (ISDN retard) in patients with coronary disease].
    Smolarz A; Seeliger S; Glocke M
    Med Welt; 1981 Apr; 32(14A):548-53. PubMed ID: 6787385
    [No Abstract]   [Full Text] [Related]  

  • 19. [Echocardiography during exercise and coronary disease].
    Fedele F; Agati L; Penco M; Arata L; Pastore LR; Giannico S
    Boll Soc Ital Cardiol; 1979; 24(8):817-32. PubMed ID: 551806
    [No Abstract]   [Full Text] [Related]  

  • 20. [Steady state kinetics of isosorbide-5-mononitrate in patients with coronary disease].
    Mannebach H; Ohlmeier H; von Möllendorff E; Gleichmann U; Abshagen U
    Med Welt; 1981 Apr; 32(14A):517-20. PubMed ID: 7242311
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 4.